Excelsior Biopharma Inc (6496) Fair Value & Analysis
Healthcare · TW · Market cap 1.1B TWD
Fair value as of: Jul 12, 2026
From 3 valuation models · updated today
Fair value updated Jul 12, 2026 — revised from 77.70 TWD to 8.39 TWD (−89.2%) since Jun 24, 2026. Share price +0.6% over the past month.
Price vs Fair Value (12 months)
12‑month range 22.85 TWD – 30.20 TWD · fair‑value band 7.78 TWD – 9.29 TWD · the 24.20 TWD price screens above the 8.39 TWD fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Excelsior Biopharma Inc (6496) currently trades at 24.20 TWD, while our model-based Fair Value estimate is 8.39 TWD — implying the stock looks roughly 65.3% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Excelsior Biopharma Inc generated revenue of 906M TWD at a net margin of -21.7%. Revenue grew 3.9% year over year. It earns a return on equity of -23.3%. Net debt stands at 106M TWD. Fundamentals as of Jul 12, 2026
Our scenario range runs from 7.78 TWD (bear case) to 9.29 TWD (bull case); at 24.20 TWD, the current price sits above that range. The share trades about 21% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside — at -65%, 6496 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products. In addition, it is involved in importing and exporting of active pharmaceutical ingredients, food, and cosmeceuticals; development of cosmetics; research, importing and exporting of technologies; and pharmaceutical technologies transfer. The company was formerly known as Excelsior Enterprise Co., Ltd. and changed its name to Excelsior Biopharma Inc. in June 2003. Excelsior Biopharma Inc. was founded in 1986 and is headquartered in Taipei, Taiwan.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Excelsior Biopharma Inc reported revenue of 898M TWD in FY2025 versus 1.3B TWD in FY2021, a compound −9.5%/yr. Reported net income was −183M TWD in FY2025.
Is 6496 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Excelsior Biopharma Inc (6496) undervalued?
What is the fair value of 6496?
What is the quality score of 6496?
What is the revenue of Excelsior Biopharma Inc (6496)?
What is the net profit margin of 6496?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Excelsior Biopharma Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.